Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.49 |
| ▸ | TERT | O14746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | ITGAL | P20701 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247265 | 1.00 | CA2 (0.50) | CA2CA1ALOX5TERTKDM4E | |
| SCHEMBL407185 | 1.00 | CA2 (0.50) | CA2CA1ALOX5TERTKDM4E | |
| SCHEMBL31099231 | 0.89 | CA2 (0.51) | CA2CA1PDE5AMMECA12 | |
| SCHEMBL12983737 | 0.89 | KDM4E (0.55) | CA2CA1KDM4EALDH1A1LMNA | |
| SCHEMBL11135743 | 0.87 | ALOX5 (0.41) | CA2CA1ALOX5TERTKDM4E | |
| SCHEMBL8485450 | 0.86 | CA2 (0.50) | CA2CA1ALOX5TERTPDE5A | |
| SCHEMBL8488564 | 0.86 | CA2 (0.50) | CA2CA1ALOX5TERTPDE5A | |
| SCHEMBL8487702 | 0.84 | ALOX5 (0.54) | ALOX5TERTKDM4EALDH1A1LMNA | |
| SCHEMBL8488000 | 0.84 | ALOX5 (0.54) | ALOX5TERTKDM4EALDH1A1LMNA | |
| SCHEMBL21149386 | 0.84 | ALOX5 (0.48) | CA2CA1ALOX5HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365945-B2 | Urinary microbiomic profiling | Convergent Genomics, Inc. (US) | 2025-07-22 | — | — | US | claimed |
| US-20250155433-A1 | FLUORESCENT SENSORS FOR DETECTION OF SIDEROPHORES AND OTHER MOLECULES PRODUCED BY BACTERIAL PATHOGENS | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2025-05-15 | — | — | US | claimed |
| US-20250009891-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | UNIVERSITY OF NOTRE DAME DU LAC | 2025-01-09 | — | — | US | claimed |
| WO-2023122585-A2 | FLUORESCENT SENSORS FOR DETECTION OF SIDEROPHORES AND OTHER MOLECULES PRODUCED BY BACTERIAL PATHOGENS | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2023-06-29 | — | — | WO | claimed |
| US-20210310071-A1 | URINARY MICROBIOMIC PROFILING | Convergent Genomics, Inc. | 2021-10-07 | — | — | US | claimed |
| EP-3826646-A1 | URINARY MICROBIOMIC PROFILING | Convergent Genomics, Inc. (US) | 2021-06-02 | — | — | EP | claimed |
| WO-2020023630-A1 | URINARY MICROBIOMIC PROFILING | Convergent Genomics, Inc. (US) | 2020-01-30 | — | — | WO | claimed |
| US-20190352691-A1 | PATHOGEN DETECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-11-21 | — | — | US | claimed |
| US-9828627-B2 | Reducing DNA damage during sample preparation and sequencing using siderophore chelators | ILLUMINA CAMBRIDGE LIMITED (GB) | 2017-11-28 | — | — | US | claimed |
| US-9765294-B2 | Chemically defined medium for the industrial scale culture of a species of Bordetella | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2017-09-19 | — | — | US | claimed |
| US-20160319322-A1 | PATHOGEN DETECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-11-03 | — | — | US | claimed |
| US-20160222344-A1 | A CHEMICALLY DEFINED MEDIUM FOR THE INDUSTRIAL SCALE CULTURE OF A SPECIES OF BORDETELLA | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2016-08-04 | — | — | US | claimed |
| EP-3044308-A1 | A CHEMICALLY DEFINED MEDIUM FOR THE INDUSTRIAL SCALE CULTURE OF A SPECIES OF BORDETELLA | GlaxoSmithKline Biologicals S.A. (BE) | 2016-07-20 | — | — | EP | claimed |
| CN-105518122-A | A chemically defined medium for the industrial scale culture of a species of bordetella | GLAXOSMITHKLINE BIOLOGICALS SA | 2016-04-20 | — | — | CN | claimed |
| WO-2015121704-A2 | PATHOGEN DETECTION | MILLER MARVIN J (US) | 2015-08-20 | — | — | WO | claimed |
| WO-2015036953-A1 | A CHEMICALLY DEFINED MEDIUM FOR THE INDUSTRIAL SCALE CULTURE OF A SPECIES OF BORDETELLA | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2015-03-19 | — | — | WO | claimed |
| US-20110268818-A1 | NGAL-BINDING SIDEROPHORES AND USE THEREOF TO TREAT IRON DEFICIENCY AND IRON OVERLOAD | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-11-03 | — | — | US | claimed |
| EP-2330897-A1 | NGAL-BINDING SIDEROPHORES AND USE THEREOF TO TREAT IRON DEFICIENCY AND IRON OVERLOAD | The Trustees of Columbia University in the City of New York (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010033847-A1 | NGAL-BINDING SIDEROPHORES AND USE THEREOF TO TREAT IRON DEFICIENCY AND IRON OVERLOAD | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-25 | — | — | WO | claimed |
| EP-0005346-B1 | ENTEROCHELIN COMPLEXES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND A PROCESS FOR PREPARING THEM | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-03-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009891-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | MGAM, OPRM1, BPGM | CA2 2226/4885CA1 2418/4885ALOX5 1948/4885 |
| US-20110268818-A1 | NGAL-BINDING SIDEROPHORES AND USE THEREOF TO TREAT IRON DEFICIENCY AND IRON OVERLOAD | SLC40A1, HAMP, TFRC | CA2 1383/4885CA1 2702/4885ALOX5 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.